Integrated Molecular Meta-Analysis of 1,000 Pediatric High-Grade and Diffuse Intrinsic Pontine Glioma. by Mackay, A et al.
Cancer Cell
 
Integrated molecular meta-analysis of 1000 paediatric high grade and diffuse intrinsic
pontine glioma
--Manuscript Draft--
 
Manuscript Number: CANCER-CELL-D-17-00318R4
Full Title: Integrated molecular meta-analysis of 1000 paediatric high grade and diffuse intrinsic
pontine glioma
Article Type: Research Article
Keywords: genome;  exome;  methylation;  histone;  Glioblastoma;  DIPG
Corresponding Author: Chris Jones
Institute of Cancer Research
Sutton, Surrey UNITED KINGDOM
First Author: Alan Mackay
Order of Authors: Alan Mackay
Anna Burford
Diana Carvalho
Elisa Izquierdo
Janat Fazal Salom
Kathryn Taylor
Lynn Bjerke
Matthew Clarke
Mara Vinci
Meera Nandhabalan
Sara Temelso
Sergey Popov
Valeria Molinari
Pichai Raman
Angela Waanders
Harry Han
Saumya Gupta
Lynley Marshall
Stergios Zacharoulis
Sucheta Vaidya
Henry Mandeville
Leslie Bridges
Andrew Martin
Safa Al-Sarraj
Christopher Chandler
Ho-Keung Ng
Xiangang Li
Kun Mu
Powered by Editorial Manager® and ProduXion Manager® from Aries Systems Corporation
Saoussen Trabelsi
Dorra H'mida-Ben Brahim
Alexei Kisljakov
Dmitry Konovalov
Andrew Moore
Angel Montero Carcaboso
Mariona Sunol
Carmen de Torres
Ofelia Cruz
Jaume Mora
Ludmila Shats
Joao Stavale
Lucas Bidinotto
Rui Reis
Natacha Entz-Werle
Michael Farrell
Jane Cryan
Darach Crimmins
John Caird
Jane Pears
Michelle Monje
Marie-Anne Debily
David Castel
Jacques Grill
Cynthia Hawkins
Hamid Nikbakht
Nada Jabado
Suzanne Baker
Stefan Pfister
David Jones
Maryam Fouladi
Andre von Bueren
Michael Baudis
Adam Resnick
Chris Jones
Abstract: Paediatric high-grade glioma and diffuse intrinsic pontine glioma are rare, incurable
childhood brain tumours with differing biology to adult cancers. We collated data from
157 unpublished cases and 20 publically available datasets in an integrated analysis
comprising 1067 unique patients across all anatomical compartments of the CNS.
Distinct clinicopathological and molecular subgroups are defined by specific histone
mutations, with novel co-segregating mutations identified including loss of FBXW7 in
H3.3G34R/V, TOP3A rearrangements in H3.3K27M, and BCOR mutations in
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H3.1K27M. Histone wild-type subgroups are refined by the presence of key oncogenic
events or methylation profiles more closely resembling lower-grade tumours. Genomic
aberrations increase with age, highlighting the infant population as biologically and
clinically distinct. Across the whole cohort, we identify novel pathway dysregulation in
small subsets of tumours, further defining the molecular diversity of the disease,
opening up novel avenues for biological study and providing a basis for functionally-
defined future treatment stratification.
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Summary 
We collated data from 157 unpublished cases of pediatric high grade glioma and diffuse 
intrinsic pontine glioma and 20 publicly available datasets in an integrated analysis of 
>1000 cases. We identified co-segregating mutations in histone-mutant subgroups 
including loss of FBXW7 in H3.3G34R/V, TOP3A rearrangements in H3.3K27M, and 
BCOR mutations in H3.1K27M. Histone wild-type subgroups are refined by the presence 
of key oncogenic events or methylation profiles more closely resembling lower-grade 
tumors. Genomic aberrations increase with age, highlighting the infant population as 
biologically and clinically distinct. Uncommon pathway dysregulation is seen in small 
subsets of tumors, further defining the molecular diversity of the disease, opening up 
avenues for biological study and providing a basis for functionally-defined future 
treatment stratification. 
 
 
Significance 
High-grade and diffuse intrinsic pontine glioma in children are rare, incurable brain 
tumors with differing biology to adult cancers. An integrated genomic, epigenomic and 
transcriptomic analysis of >1000 cases across all anatomical compartments of the CNS 
defines robust clinicopathological and molecular subgroups with distinct biological 
drivers. As modern classification schemes begin to recognize the diversity of this 
disease in the pediatric population, we provide a framework for meaningful further 
subcategorization and identify subgroup-restricted therapeutic targets.  
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Introduction 
Pediatric glioblastoma (pGBM) and diffuse intrinsic pontine glioma (DIPG) are high 
grade glial tumors of children with a median overall survival of 9-15 months, a figure 
that has remained unmoved for decades (Jones et al., 2012). Although relatively rare 
in this age group (1.78 per 100,000 population), taken together, gliomas are 
nonetheless the most common malignant brain tumors in children, and represent the 
greatest cause of cancer-related deaths under the age of 19 years (Ostrom et al., 
2015). Unlike histologically similar lesions in adults, which tend to be restricted to the 
cerebral hemispheres, diffuse high grade gliomas in childhood (pHGG) can occur 
throughout the central nervous system (CNS), with around half occuring in midline 
locations, in particular the thalamus and the pons (Jones and Baker, 2014), where 
the lack of available surgical options confers an especially poor prognosis (Kramm et 
al., 2011). Numerous clinical trials of chemotherapeutics and targeted agents 
extrapolated from adult GBM studies have failed to show a survival benefit, and more 
rationally-derived approaches based upon an understanding of the childhood 
diseases are urgently needed (Jones et al., 2016).  
 
It has become increasingly apparent that pHGG differ from their adult counterparts, 
with molecular profiling studies carried out over the last 6-7 years having 
incrementally identified key genetic and epigenetic differences in pHGG associated 
with distinct ages of onset, anatomical distribution, clinical outcome, histopathological 
and radiological features (Jones and Baker, 2014; Sturm et al., 2014). In particular, 
the identification of unique recurrent mutations in genes encoding histones H3.3 and 
H3.1 (Schwartzentruber et al., 2012; Wu et al., 2012) have demonstrated the 
distinctiveness of the pediatric disease, with the G34R/V and K27M variants 
appearing to represent different clinicopathological and biological subgroups. This 
has been recognized by the World Health Organization (WHO) classification of CNS 
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tumors, with the latest version including the novel entity, diffuse midline glioma with 
H3K27 mutation (Louis et al., 2016). Further refinements incorporating other clearly 
delineated subsets of the disease in future iterations appear likely and might prove 
clinically useful. 
 
In addition to these uniquely defining histone mutations, detailed molecular profiling 
has served to identify numerous targets for therapeutic interventions. These include 
known oncogenes in adult glioma and other tumors with an elevated frequency in the 
childhood setting (e.g. PDGFRA) (Paugh et al., 2013; Puget et al., 2012) or certain 
rare histological variants (e.g. BRAF V600E) (Nicolaides et al., 2011; Schiffman et 
al., 2010), as well as others seemingly unique to DIPG (e.g. ACVR1) (Buczkowicz et 
al., 2014; Fontebasso et al., 2014; Taylor et al., 2014a; Wu et al., 2014). Future trials 
will need to exploit these targets but also incorporate innovative designs that allow 
for selection of the patient populations within the wide spectrum of disease who are 
most likely to benefit from any novel agent (Jones et al., 2016). 
 
Despite these advances, driven by the efforts of several international collaborative 
groups to collect and profile these rare tumors, individual publications remain 
necessarily modestly sized, involving a range of different platforms and analytical 
techniques. This leaves certain subgroups poorly represented across studies, widely 
differing individual gene frequencies in different cohorts, and an inability to draw 
robust conclusions across the whole spectrum of the disease. We have gathered 
together publicly available data, supplemented with 157 new cases, in order to 
provide a statistically robust, manually annotated resource cohort of >1000 such 
tumors for interrogation.  
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Results 
Sample cohort 
In total, we obtained data from clinically annotated high grade glioma (WHO 2007 
grade III or IV) or diffuse intrinsic pontine glioma (radiologically diagnosed, grades II-
IV) in 1067 unique cases (Figure S1A). These were predominantly from children but 
also included young adults, in order to capture more H3F3A G34R/V mutations, as 
well as to explore an otherwise under-studied population. There was a median age at 
diagnosis of 9.8 years, and 982 cases aged 21 years or younger (Table S1). These 
included 910 taken from 20 published series (Barrow et al., 2011; Bax et al., 2010; 
Buczkowicz et al., 2014; Carvalho et al., 2014; Castel et al., 2015; Fontebasso et al., 
2014; Fontebasso et al., 2013; Grasso et al., 2015; International Cancer Genome 
Consortium PedBrain Tumor, 2016; Khuong-Quang et al., 2012; Korshunov et al., 
2015; Paugh et al., 2011; Paugh et al., 2010; Puget et al., 2012; Schwartzentruber et 
al., 2012; Sturm et al., 2012; Taylor et al., 2014a; Wu et al., 2012; Wu et al., 2014; 
Zarghooni et al., 2010), and 157 unpublished cases. The vast majority of samples 
were obtained pre-treatment (biopsy or resection, n=913), as opposed to post-
therapy (relapse or autopsy, n=146). Samples were classified as occuring within the 
cerebral hemispheres (n=482), brainstem (n=323 in pons, 322 of which were DIPG; 
three additional cases in the midbrain and one in the medulla) or other non-brainstem 
midline locations (n=224, predominantly thalamus, but also cerebellum, spinal cord, 
ventricles and others; referred to as ‘midline’ for simplicity throughout) (Figure 1A). 
There was a significant association of anatomical location with age of diagnosis, with 
medians of 13.0 years for hemispheric, 10.0 years for midline, and 6.5 years for 
DIPG, respectively (p<0.0001, ANOVA; all pairwise comparisons adjusted p<0.0001, 
t-test) (Figure 1B), in addition to clinical outcome, with a median overall survival of 
18.0 months for hemispheric tumors (2 year overall survival 32%), 13.5 months for 
midline (2 year overall survival 21.4%), and 10.8 months for DIPG (2 year overall 
survival 5.2%; p<0.0001 for all pairwise comparisons, log-rank test) (Figure 1C). 
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Children 3 years of age and younger had a markedly improved clinical outcome 
(p=0.0028, log-rank test), though this benefit was largely restricted to children 1 year 
and under (n=40, 2 year survival 61%, p<0.0001, log-rank test), with this association 
significant in all anatomical locations (p=0.0402, hemispheric; p<0.0001, midline; 
p=0.00286, pons, log-rank test). There were however proportionally fewer midline 
and pontine tumors in < 1 year olds compared with 1-3 years (12/40, 30.0% vs 46/85, 
45.9%, p=0.0131 Fishers exact  test) (Figure S1B,C). 
 
Molecular subgrouping  
Hotspot mutation data for the genes encoding histone H3 were available or newly 
generated for 903 cases. At minimum, this included Sanger sequencing for H3F3A 
(H3.3) and HIST1H3B (H3.1), however the absence of wider screening or next-
generation sequencing data for 310 cases annotated as H3 wild-type means we 
cannot rule out rare variants in other H3.1 (n=2 HIST1H3C) or H3.2 genes (n=2 
HIST2H3C) in those cases. In total, the cohort comprised 67 H3.3G34R/V (n=63 
G34R, n=4 G34V), 316 H3.3K27M, 66 H3.1/3.2K27M (n=62 HIST1H3B, n=2 
HIST1H3C, n=2 HIST2H3C) and 454 wild-type. There were profound distinctions in 
anatomical location (p<0.0001, Fishers exact test) (Figure 1D), age at diagnosis 
(p<0.0001, ANOVA; all pairwise comparisons adjusted p<0.0001, t-test) (Figure 1E), 
and overall survival (p<0.0001, log-rank test) (Figure 1F). H3.3G34R/V tumors were 
almost entirely restricted to the cerebral hemispheres (accounting for 16.2% total in 
this location, particularly parietal and temporal lobes), were found predominantly in 
adolescents and young adults (median 15.0 years), and had a longer overall survival 
compared to other H3 mutant groups (median 18.0 months, 2 year overall survival 
27.3%, p<0.0001 vs H3.3K27M, p=0.00209 vs H3.1H27M, log-rank test). H3.3K27M 
were spread throughout the midline and pons, where they account for 63.0% DIPG 
and 59.7% non-brainstem midline tumors. In all locations (including 10 cases 
reported to present in the cortex), these mutations conferred a significantly shorter 
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time to death from disease (overall median 11 months, 2 year overall survival 4.7%) 
(Figure S1D-F). H3.1/3.2K27M were highly specific to the pons (21.4% total) where 
they represent a younger age group (median 5.0 years) with a significantly longer 
overall survival (median 15.0 months) than H3.3K27M (p=0.00017, log-rank test) 
(Figure S1F). In multivariate analysis incorporating the histone mutations alongside 
age, WHO grade and gender, K27M mutations in both H3.3 and H3.1 are 
independently associated with shorter survival (p<0.0001, Cox proportional hazards 
model). 
 
BRAF V600E status was available for 535 cases, with mutant cases (n=32, 6.0%) 
present only in midline and hemispheric locations, and conferring a significantly 
improved prognosis (2 year survival 67%, p<0.0001, log-rank test) (Figure S1G-I). 
There was additional annotation for IDH1 R132 mutation status in 640 cases (n=40, 
6.25%), representing a forebrain-restricted, significantly older group of patients 
(median 17.0 years, p<0.0001, t-test) with longer overall survival (2 year survival 
59%, p<0.0001, log-rank test) (Figure S1J-L).  
 
For 441 cases, Illumina 450k methylation BeadArray data was available, which 
provides robust classification into clinically meaningful epigenetic subgroups marked 
by recurrent genetic alterations (Korshunov et al., 2015, Korshunov et al., 2017). We 
used the Heidelberg brain tumor classifier to assign tumors into following subgroups 
– H3G34R/V (n=51), H3K27M (n=119), HGG wild-type (n=156), IDH1 (n=36), LGG-
like (n=27), PXA-like (n=43) and ‘other’ (n=9) (Figure S2A), visualized by hierarchical 
clustering (Figure 2A) (Table S2). As previously reported, these subgroups have 
profound differences in anatomical location (Figure 2B), age at diagnosis (p<0.00001 
ANOVA) (Figure 2C) and overall survival (p<0.0001, log-rank test) (Figure 2D), with 
LGG-like group representing a younger cohort (median 4.0 years, 10/16 infant cases 
under 1 year, p<0.0001 Fishers exact test) with excellent prognosis (2 year survival 
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74%, p<0.0001 vs wild-type, log-rank test), whilst the PXA-like group are enriched for 
BRAF V600E mutations (19/34, 56%) and carry an intermediate risk (median 38 
months, 2 year survival 56%, p=0.00423 vs wild-type, log-rank test). After removing 
the PXA- and LGG-like groups, the remaining histone H3/IDH1 wild-type tumors had 
a 2 year survival of 23.5% (median overall survival 17.2 months). MGMT promoter 
methylation was significantly enriched in the H3G34R/V (65.1%, globally 
hypomethylated) and IDH1 (78.1%, globally hypermethylated) groups, and largely 
absent from H3K27M tumors (4.5%, all tests versus rest, p<0.0001 Fishers exact 
test) (Figure S2B). Total methylation was lowest in H3G34R/V (median beta value 
0.452), and highest in the IDH subgroup (median beta value 0.520), as previously 
reported (Sturm et al., 2012), however was also found to be significantly elevated in 
PXA-like tumors (median beta value 0.501, p<0.0001 t-test) (Figure S2C). 
 
DNA copy number 
High-quality DNA copy number profiles were obtained from 834 unique cases of 
pHGG/DIPG, taken from BAC and oligonucleotide arrays (n=112), SNP arrays 
(n=128), 450k methylation arrays (n=428) and whole genome or exome sequencing 
(n=325) (Table S3). Clustering on the basis of segmented log2 ratios highlighted 
some of the defining chromosomal features of the pediatric disease, including 
recurrent gains of chromosome 1q, and losses of chromosomes 13q and 14q (Figure 
3A). There are also a significant proportion of tumors (n=147, 17.6%) with few if any 
DNA copy number changes, with no bias towards lower-resolution platforms 
(p=0.134, Fishers exact test), and the presence of other molecular markers obviating 
concerns of a substantial normal tissue contamination. These cases were found 
throughout the CNS, were younger at diagnosis (7.0 years versus 10.3, p<0.0001, t-
test) and had a longer overall survival (median 18.0 versus 14.0 months, p=0.0107 
log-rank test) (Figure S3A). Common large scale chromosomal alterations with 
prognostic significance included loss of 17p (n=156), which targets TP53 at 17p13.1 
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and confers a shorter overall survival in tumors of all locations and all subgroups 
(Figure S3B), and gains of 9q (n=108), more broadly encompassing a region of 
structural rearrangement on 9q34 in medulloblastoma (Northcott et al., 2014), and 
correlating with shorter overall survival in multiple pHGG/DIPG subgroups (Figure 
S3C).  
 
We used GISTIC in order to determine subgroup-specific copy number drivers based 
on focality, amplitude, and recurrence of alterations. The most common focal events 
were the previously described high level amplifications (Figure 3B) at 4q12 
(PDGFRA/KIT/KDR, n=77), 2p24.3 (MYCN/ID2, n=42), chromosome 7 (7p11.2 
(EGFR, n=32), 7q21.2 (CDK6, n=14), and 7q31.2 (MET, n=19)) (Figure S3D-F), as 
well as focal deletions (Figure 3C) at 9p21.3 (CDKN2A/CDKN2B, n=102) (Figure 
S3G). Amplifications conferred a shorter overall survival, and CDKN2A/CDKN2B 
deletion a better prognosis, either across the whole cohort or selected subgroups 
(Figure S3B-G). Additionally, the aggregated data identified less frequent alterations, 
recurrent across multiple studies, identifying pHGG/DIPG candidates including NFIB 
(nuclear factor I B, 9p23-p22.3, n=4), GAB2 (GRB2-associated binding protein 2, 
11q14.1, n=4), SMARCE1 (SWI/SNF related, matrix associated, actin dependent 
regulator of chromatin, subfamily e, member 1, 17q21.2, n=4) and others (Figure 
3B,C).  
 
Subgroup-specific alterations 
When IDH1-mutant tumors were removed and the cohort restricted to those cases 
for which histone H3 status was available, we were able to investigate subgroup-
specific DNA copy number changes in 705 pHGG/DIPG (Figure 4A). Applying 
GISTIC within these case sets revealed specific focal events enriched within 
individual subgroups, including AKT1 amplifications in H3.3G34R/V, MYC and 
CCND2 amplification in H3.3K27M, and MYCN/ID2, MDM4/PIK3C2B, and KRAS 
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amplification in H3 wild-type (Figure 4B) (Table S4). These latter events were 
generally restricted to hemispheric tumors, whilst MYCN/ID2 were enriched in H3 
wild-type DIPG (Figure S4A). H3.1K27M tumors generally lacked amplifications / 
deletions, but were instead characterised by frequent gains of 1q and the whole of 
chromosome 2, and the loss of 16q (Figure 4C). PXA-like tumors had frequent 
CDKN2A/B deletions and a unique loss at 1q, associated with shorter overall survival 
within this group (Figure S4B) 
 
Whole arm losses were also enriched in H3.3G34R/V tumors, specifically 3q, 4q, 5q 
and 18q, where smallest regions of overlap were in some instances able to narrow 
the common region to a handful of candidate genes (Figure S4C). On chromosome 
4q this appeared to target FBXW7 at 4q31.3, also aligning with the GISTIC data 
(Figure 5A). Across three independent platforms, gene expression over the whole 
arm was significantly lower when 4q was lost (Agilent, p=0.00231; Affymetrix, 
p=0.000102; RNAseq, p=0.0398; Wilcoxon signed-rank test). (Figure S5A) (Table 
S5). There were also four patients with 3 different somatic coding mutations identified 
(below), two truncating and one missense, three of which were in hemispheric 
tumors, and two with H3F3A G34R (Figure 5B). In cases with 4q loss, median 
FBXW7 gene expression was reduced compared to those with normal copy number 
(Agilent, p=0.029; Affymetrix, p=0.015; RNAseq, p=0.4; Mann-Whitney U test) 
(Figure 5C). 
 
Within H3.3K27M tumors, we identified a recurrent amplification at 17p11.2 (n=17; 
170kb-11.96Mb), across multiple platforms and significantly enriched in DIPGs, 
which appears to target TOP3A within these tumors (Figure 5D). Where available 
(n=6) (Figure S5B), whole genome sequencing data reveals this occurs via complex 
intra- and inter-chromosomal rearrangements (Figure 5E) leading to increased 
mRNA expression of TOP3A in amplified versus non-amplified cases in Agilent 
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(n=1), Affymetrix and RNAseq (p=0.011 and p=0.016 respectively, Mann-Whitney U 
test) data (Figure 5F) (Table S5). In an integrated dataset, TOP3A was the most 
differentially expressed gene in the region in amplified cases (adjusted p=0.00856 
Mann-Whitney U test). We further identified a single somatic missense mutation 
(C658Y) in an additional case of DIPG, and taken together, TOP3A alterations were 
mutually exclusive with ATRX deletion/mutations found in H3.3K27M DIPG (0/13).  
 
Whole genome and exome sequencing  
Out of 372 sequenced cases (n=118 whole genome, n=247 exome, 7 both), we were 
able to retrieve raw data from 351 for integration of somatic variant calling (Table S6) 
and DNA copy number changes. Of these, RNAseq data was available for 47, 
allowing for candidate fusion gene nomination in 150 cases (RNAseq or WGS, 
restricted to high-confidence nominations in relevant pathway-associated genes, 
Table S6). Taking a conservative approach to variant calling given the disparate 
sequencing coverage (median 88x, range 16-295x), capture platforms, and 
availability of germline data, we report a median number of somatic single nucleotide 
variants (SNVs) and insertion/deletions (InDels) of 12, with 97% cases in the range 
0-305. DNA copy neutral cases had significantly fewer somatic mutations (median 
8.37 vs 21.32 SNVs/InDels per case), with those copy neutral cases also having no 
detectable mutations falling into the youngest age group (median=3.9 years). There 
was only a modestly elevated mutation rate between samples taken post- compared 
to pre-treatment (1.5-fold, p=0.056, t-test) (Figure S6A). However, 11 cases had a 
vastly increased mutational burden, described as a hypermutator phenotype (median 
13,735 SNVs/InDels, range 852-38,250), with distinctive mutational spectra from 
non-hypermutated pHGG/DIPG (Shlien et al., 2015) including three cases with 
plausible somatic activating POLE mutations (Figure S6B). IDH1-mutant cases were 
again excluded (n=14), with genetic profiles identical to that described in adults for 
astrocytic tumors (13/14 TP53, 7/14 ATRX mutations), and oligodendroglial tumors 
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(1p19q co-deletion, TERT promoter, CIC, FUBP1 mutations) entirely absent (Figure 
S6C). We were thus left with an integrated dataset of 326 pHGG/DIPG, providing 
robust annotation of the most frequently altered genes across histone H3 subgroups 
and anatomical locations (Figure 6A). As well as known associations such as 
hemispheric H3.3G34R/V and TP53 / ATRX (18/20, 90%; p=0.0001), midline 
H3.3K27M and FGFR1 (8/39, 20.5%; p=0.212, not significant), pontine H3.1K27M 
and ACVR1 (28/33, 84.8%; p<0.0001), and PXA-like GBM with BRAF V600E (17/28, 
60.7%; p<0.0001), we also identified previously unrecognized co-segregating 
mutations including H3.3G34R/V and ARID1B (2/20, 10%; p=0.0720), H3.3K27M 
DIPG and ATM and ASXL1 (5/93, 10.7%; p=0.0473), H3.1K27M and BCOR (6/37, 
16.2%; p=0.0022, all Fishers exact test) (Figure S6D). We also identified recurrent 
events in genes such as PTPN23 (protein tyrosine phosphatase, non-receptor type 
23, n=5), SOX10 (SRY-box 10, n=5), SRCAP (Snf2-related CREBBP activator 
protein, n=5), DEPDC5 (DEP domain-contain 5, member of GATOR complex, n=4), 
SGK223 (PEAK1-related kinase activating pseudokinase, n=4), and others (Figure 
6B). 
 
Integrated pathway analysis 
Many of the rare variants we identified (Figure S6E) were found in genes associated 
with intracellular signalling pathways and processes more commonly targeted by 
high frequency events, often in a mutually exclusive manner. In total, 297/326 
(91.1%) of cases were found to harbor genetic alterations in one or more of nine key 
biological processes (Figure 7A). These included well-recognized pathways such as 
DNA repair (198/326, 60.7%), largely driven by TP53 mutations (n=160) but also by 
common mutually exclusive (p<0.0001, Fishers exact test) activating truncating 
alterations in PPM1D (n=18), as well as heterozygous mutations in a diverse set of 
genes including those involved in homologous recombination (ATM, BRCA2, BLM, 
ATR, PALB2, RAD50, RAD51C) and numerous Fancomi Anemia genes (BRIP1, 
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FANCM, FANCA, FANCG), amongst others (Figure S7A). Although TP53 is almost 
always found in concert with H3.3G34R/V in the cerebral hemispheres, these 
additional DNA repair pathway mutations were enriched in H3.3K27M DIPG (36/68, 
52.9%). Also co-segregating with H3.3G34R/V and TP53 is ATRX, although 
mutations/deletions of the latter gene are also frequently found in conjunction with 
H3.3K27M (28/54, 51.8%). ATRX accounts for a large proportion of the cases 
harboring mutations in genes coding for chromatin modifiers (54/118, 45.8%), 
however there is a diverse set of readers, writers and erasers additionally targeted at 
lower frequency, especially in DIPG, including the previously mentioned BCOR 
(n=14) and ASXL1 (n=6) in addition to SETD2 (n=8), KDM6B (n=6), SETD1B (n=5) 
and ARID1B (n=5) amongst many others (Figure S7B).  
 
Whilst CDKN2A/CDKN2B deletions were almost entirely absent from DIPG (1/154, 
0.65%), dysregulation of the G1/S cell cycle checkpoint was common throughout 
anatomical locations and subgroups (82/326, 25.2%), with amplifications of CCND2 
and deletions of CDKN2C predominating in the pons (n=5/7 and 5/5 DIPG 
respectively), in contrast to recurrent homozygous RB1 deletions and CDK6 
amplifications (n=6/7 and 4/6 hemispheric) (Figure S4A) (Figure S7C). 
 
Subgroup-specific dysregulation was also observed when considering discrete 
components of the RTK-PI3K-MAPK pathway. In total, 201/326 (61.7%) cases 
harbored alterations in any given node, however for H3.3G34R/V this was 
predominantly at the RTK level (11/20, n=9 PDGFRA) (Figure S7D) whereas 
H3.1K27M cases were enriched for PI3K/mTOR alterations (17/37, n=9 PIK3CA, n=5 
PIK3R1) (Figure S7E) and H3 wild-type cases harbored the highest frequency of 
MAPK alterations (mainly BRAF V600E in PXA-like, n=5/10 plus one NF1) (Figure 
S7F). NRTK1-NRTK3 fusions were enriched in the infant group (4/6 fusions under 1 
year old, median age 3.25 versus 8.5 years, p=0.00033, t-test) (Figure S7D). We 
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further identified mutations in genes regulating mTOR signalling, including TSC2 
(n=3), RPTOR, and MTOR itself (both n=2), as well as a diverse series of SNVs and 
fusion candidates in MAPKs across all subgroups and locations (MAP2K7, 
MAP3K15, MAP3K4 and others) (Figure S7F).  
 
BMP signalling was significantly enriched in H3.1K27M DIPG due to the strong 
correlation with ACVR1 mutations, however alterations in other pathway members 
such as amplification of ID2 (n=10) or ID3 (n=3) and mutations in BMP3 (n=5), 
BMP2K (n=3) and others across locations and subgroups extends the proportion of 
tumors for which this pathway may be relevant (62/326, 18.7%) (Figure S7G). There 
was also a subset of cases harboring alterations in members of the WNT signalling 
pathway (16/326, 4.9%), including AMER1, APC (both n=3), and WNT8A, WNT9A, 
PLAGL2 and TCF7L2 (all n=2) (Figure S7H). 
 
Uniquely, the accumulated data uncovered a series of additional processes involved 
in maintenance of DNA replication, genome integrity or transcriptional fidelity, 
targeted by infrequent but mutually exclusive alterations in pHGG and DIPG. These 
included mutations in splicing factors (SF3A1, SF3A2, SF3A3, SF3B1, SF3B2, 
SF3B3, total n=10), sister chromatid segregation (STAG2, STAG3, ESPL1, total 
n=9), pre-miRNA processing (DICER, DROSHA, total n=4), DNA polymerases 
(POLK, POLQ, POLR1B, total n=4) as well as genes involved in centromere 
(CENPB, n=3) and telomere maintenance (PML, n=2; TERT, n=7) (Figure S7I). 
TERT promoter mutations were found in 5/326 (1.5%) cases, however alternative 
lengthening of telomeres (ALT) status was only available for 26 cases, though the 5 
ALT-positive samples (19.2%) were mutually exclusive with TERT alterations.  
 
We incorporated the integrated dataset into a pathway enrichment analysis 
(significant gene sets, FDR<0.05, visualized as interaction networks by Cytoscape 
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Enrichment Map), in order to gain additional insight into dysregulated biological 
processes. In addition to the subgroup-specific differential targeting of distinct nodes 
within common signalling pathways already described (e.g. RTK, PI3K/mTOR and 
MAPK), additional dysregulated processes across the diversity of the disease were 
identified (Figure 7B). This revealed the perhaps not unexpected dysregulation of 
numerous developmental and CNS-associated gene sets (various immature organ 
systems, neuronal communication) but also previously unrecognized areas such as 
nuclear transport, cell migration and the immune response (Table S7), which may 
provide further insight into disease biology as well as represent potential therapeutic 
strategies targeting key regulators of tumor phenotype. Indeed, neuronal 
communication with pGBM and DIPG cells is a recently demonstrated 
microenvironmental driver of pediatric glioma growth (Venkatesh et al., 2015). 
 
Histone H3/IDH1 wild-type subgroups 
Finally, we wanted to explore those cases absent any histone H3 or IDH1 mutations 
in more depth. Using a t-statistic based stochastic neighbor embedding (t-SNE) 
projection of the 450k methylation data, we identified three distinct clusters of tumors 
separate from the G34, K27 and IDH1 groups (Figure 8A). Consensus clustering of 
the H3/IDH1 wild-type cases alone confirmed the presence of three robust 
subgroups (Figure 8B), which were also recapitulated by unsupervised hierarchical 
clustering of the 10,000 probe classifier subset (Figure 8C). These groups included a 
largely hemispheric set of tumors containing, but not restricted to, the PXA-like and 
LGG-like subgroups (WT-A). These tumors were driven by either BRAF V600E, NF1 
mutations, or fusions in RTKs including MET, FGFR2 and NTRK2,3 (Figure 8D). 
Although including many younger patients, the ages varied widely (Figure 8E). 
Regardless, this group had the best overall survival (median=63 months, p<0.0001 
vs rest, log-rank test) (Figure 8F), with the non-PXA/LGG-like tumors within this 
group themselves having an extended median survival time of 38 months (p=0.00928 
 17 
vs other H3/IDH1 wild-types, log-rank test). Taking an integrated gene expression 
profiling dataset (Figure S8A-E), these tumors were found to have up-regulation of 
gene signatures associated with cytokine signalling and cell junction organization 
(Figure S8F,G). A second group of tumors (WT-B) were found in all anatomical 
compartments, and were distinguished chromosome 2 gains (Figure 8C) and most 
notably by high level amplifications in EGFR, CDK6 and MYCN (p=0.00033, 
p=0.0299, p=0.00037 respectively, Fishers exact  test), with an imperfect overlay to 
the classifier “GBM_pedRTK” and “GBM_MYCN” groups (Figure 8D). This group had 
strong upregulation of MYC target genes, and had the poorest overall survival 
(median=14 months) (Figure 8F). The remaining cases encompassed a methylation 
classifier group described as “HGG_MID”, though in fact were split 80:20 
hemispheric:midline (WT-C) (Figure 8C). This group was enriched for chromosome 
1p and 20q loss, 17q gain (p=0.00595, p=0.0286, p=0.0478 respectively, Fishers 
exact test) (Figure 8C), harbored PDGFRA and MET amplifications (p=0.0159, 
Fishers exact test) (Figure 8D), and was strongly associated with the adult GBM-
defined ‘Proneural’ gene signature. These patients had a median survival of 18 
months.  
 
Although there remain tumors without detectable genetic alterations, we are 
nonetheless able to assign clinically meaningful subgroups with plausible driver 
alterations to the vast majority of pediatric HGG / DIPG. 
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Discussion 
Integrated molecular profiling has revolutionized the study of diffusely infiltrating high 
grade glial tumors in children, providing evidence for unique mechanisms of 
molecular pathogenesis reflecting their distinct developmental origins (Baker et al., 
2015; Jones and Baker, 2014). Although they are relative rare, the present study 
accumulates 1067 unique cases, a number similar to the aggregated analysis of the 
TCGA adult LGG/GBM cohorts (n=1122, with grade III included in the ‘lower grade’ 
series) (Ceccarelli et al., 2016). There are clearly the usual caveats with such 
retrospective analyses of inconsistently annotated and treated cases, the cohort 
appears to represent a clinically useful approximation of the diversity of the 
pHGG/DIPG population.  
 
In adults, the key distinction is between IDH1 mutant (G-CIMP/ATRX/TP53 or 1p19q 
co-deleted/TERT promoter mutated) and wild-type (classical, mesenchymal, PA-like) 
(Ceccarelli et al., 2016), whereas in the childhood setting IDH1 mutations were 
restricted to a small proportion (6.25%) of tumors mostly in adolescent (representing 
the tail end of an overwhelmingly adult disease), and harbored only rare examples of 
the common alterations seen in wild-type adult GBM (e.g. 4.9% EGFR 
mutation/amplification). Instead, most prominent among the differences between 
pediatric and adult studies is the frequency of hotspot mutations in genes encoding 
histone H3 variants - 2/820 (0.2%) in adults (Ceccarelli et al., 2016) versus 449/893 
(50.3%) in the present pHGG/DIPG series.  
 
The importance of recurrent H3 mutations in the childhood setting has become 
increasingly clear since their unexpected discovery in 2012 (Schwartzentruber et al., 
2012; Wu et al., 2012), with clear clinicopathological differences associated with 
distinct variants (Jones and Baker, 2014; Jones et al., 2016; Sturm et al., 2014), and 
fundamental insights into mechanisms of epigenetically-linked tumorigenesis (Bender 
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et al., 2013; Bjerke et al., 2013; Chan et al., 2013; Funato et al., 2014). Despite this, 
precisely how we can target these mutations clinically remains elusive (Grasso et al., 
2015; Hennika et al., 2017). Data from such a large series of tumors demonstrates 
the robustness of the histone-defined subgroups in terms of anatomical location, age 
of incidence, clinical outcome, methylation and gene expression profile, copy number 
changes, co-segregating somatic mutations and pathway dysregulation.  As most of 
the non-histone molecular alterations previously reported in pHGG/DIPG have been 
relatively infrequent, it is only through this accumulated dataset that we have been 
able to uncover subgroup-specific genes / processes that may play a role as 
diagnostic, prognostic or predictive markers or drug targets in these diseases.  
 
H3.3G34R/V-mutant tumors are restricted to the cerebral hemispheres and co-
segregate with ATRX and TP53 mutations; they are also the only pediatric subgroup 
to harbor frequent MGMT promoter methylation (Korshunov et al., 2015). Copy 
number profiling of 63 cases highlighted a significant enrichment of chromosomal 
arm losses at 3q, 4q, 5q and 18q, further refined by SRO and GISTIC analysis. At 
4q31.3, this identified FBXW7 as a candidate gene target of the loss. FBXW7 
encodes a member of the F-box protein family and is frequently deleted/mutated in 
cancer, supporting its tumor suppressive function (Davis et al., 2014); notably in 
relation to H3.3G34R/V it has been reported to play a role in MYC/MYCN 
stabilization through its action as a component of the SCF-like ubiquitin ligase 
complex that targets MYC/MYCN for proteasomal degradation (Welcker et al., 2004; 
Yada et al., 2004). With MYCN upregulated in H3.3G34R/V tumors through 
differential H3K36me3 binding (Bjerke et al., 2013), this observation adds to the 
mechanisms by which Myc proteins exert their influence in this subgroup, and 
provide further rationale for the observed effects of disrupting these interactions, 
such as with Aurora kinase A inhibitors which target the direct interaction between 
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the catalytic domain of Aurora-A and a site flanking Myc Box I that also binds 
SCF/FbxW7 (Richards et al., 2016).  
 
H3.3K27M tumors are found in two-thirds of DIPG and non-brainstem midline pHGG 
alike, where they are associated with a shorter overall survival in both locations, as 
well as in the small number of cases reported in the cortex. Although presumably 
reflecting a common or overlapping origin, the pattern of co-segregating mutations 
differ, e.g. PDGFRA alterations predominating in the pons, and FGFR1 variants 
being largely restricted to the thalamus (Fontebasso et al., 2014). Our analysis of 
more than 300 cases further identifies differential amplification of CCND2 (DIPG) and 
CDK4 (non-brainstem midline), and most strikingly, an amplification at 17p11.2 
involving TOP3A in H3.3K27M DIPG. This complex rearrangement often involves 
loss of the more distal part of 17p involving TP53, along with intra- or inter-
chromosomal translocations to deliver an increase in TOP3A copy number and gene 
expression. TOP3A encodes DNA topoisomerase III alpha, which forms a complex 
with BLM (Wu et al., 2000), has an important role in homologous recombination 
(Yang et al., 2010), and has been implicated in maintenance of the ALT phenotype 
(Temime-Smaali et al., 2009). Notably, TOP3A amplification/mutation was found to 
be mutually exclusive with ATRX mutation in H3.3K27M DIPG, with depletion by 
small interfering RNA reducing ALT cell survival (Temime-Smaali et al., 2008), and 
therefore represents a potential therapeutic target in this subgroup.  
 
H3.1K27M tumors by contrast are restricted to the pons, patients are younger and 
with a slightly longer survival (Castel et al., 2015), and are largely defined at the copy 
number level by whole chromosomal arm gains and losses (Taylor et al., 2014a). 
They have the well-recognized association with ACVR1 mutation (Taylor et al., 
2014b), however we also identify an enrichment of downstream PI3K pathway 
mutations (PIK3CA, PIK3R1) in comparison with the largely upstream RTK 
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alterations present in H3.3K27M DIPGs, important in designing stratified trials and 
combinatorial therapies. Further association with mutations of the BCL6 repressor 
gene BCOR, commonly altered in medulloblastomas, neuroepithelial tumors and 
sarcomas, highlights a further avenue for interventional study through its regulation 
of the SHH pathway (Tiberi et al., 2014).  
 
In H3/IDH1 wild-type cases, methylation profiling refines the heterogeneous 
collection of tumors, particularly identifying two predominantly hemispheric 
intermediate risk subgroups that classify alongside other entities (PXA-like and LGG-
like) in a larger series of better outcome tumors (WT-A). These had already been 
strongly linked with dysregulation of the MAPK pathway (BRAF V600E) (Korshunov 
et al., 2015) along with CDKN2A/CDKN2B deletion (Nicolaides et al., 2011). 
However, with molecular markers such as losses at 1q and 17p appearing to confer 
a worse outcome there may be more than one subgroup within this entity, and a co-
clustering group of H3/IDH1 wild-type tumors appeared distinctly driven by somatic 
NF1 mutation. The LGG-like tumors generally occur in very young patients, where 
the appearance of few genetic alterations and a significantly better prognosis is 
shared by the majority of infant HGG. Gene fusion events, including those targeting 
NTRKs1-NTRK3, are common in this age range. Notably this enhanced survival is 
restricted to patients diagnosed under 12 months of age, and is not recapitulated in 
the 1-3 year age group, although this is the common clinical definition of ‘infants’ in 
many centres. 
 
Excluding these morphologically high grade but biologically and clinically low grade 
tumors, the remaining H3/IDH1 wild-type cases can be further split into two poor 
outcome groups driven by EGFR / MYCN / CDK6 (WT-B) or PDGFRA / MET (WT-C) 
or amplifications. These groups overlap with other methylation-based classification 
groups (PDGFRA vs EGFR vs MYCN (Korshunov et al., 2017); “GBM_pedRTK” vs 
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“GBM_MYCN” vs “HGG_MID” (molecularneuropathology.org/mnp), however are 
uniquely defined here spanning anatomical locations and integrated with sequencing 
data. Further exploration of these heterogeneous subgroups in order to refine 
integrated molecular diagnostics to prioritize patient subpopulations for stratified 
treatment remains a priority.   
 
The remarkable biological diversity spanning pediatric malignant glioma is finally 
evidenced by the <5% tumors with a hypermutator phenotype, some of the greatest 
mutational burdens in all human cancer, and candidates for immune checkpoint 
inhibitors (Bouffet et al., 2016). Previously unrecognized processes altered in small 
subsets of tumors identified through this meta-analysis, such as the splicing 
machinery, miRNA regulation and the WNT pathway offer further areas for 
exploration. The thorough cataloguing of dysregulated molecular pathways across 
the whole spectrum of pediatric diffusely infiltrating gliomas in the present study 
provides the basis for novel therapeutic development.  
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Legends for Figures 
Figure 1 – Clinicopathological and molecular subgroups of pHGG/DIPG. (A) 
Anatomical location of all high grade glioma cases included in this study, taken from 
original publications (n=1033). Left – sagittal section showing internal structures; right 
– external view highlighting cerebral lobes. Hemispheric = dark red; non-brainstem 
midline structures = red; pons = pink. Radius of circle is proportional to the number of 
cases. Lighter shaded circles represent a non-specific designation of hemispheric, 
midline or brainstem. (B) Boxplot showing age at diagnosis of included cases, 
separated by anatomical location (n=1011). The thick line within the box is the 
median, the lower and upper limits of the boxes represent the first and third quartiles, 
and the whiskers 1.5x the interquartile range. *** adjusted p<0.0001 for all pairwise 
comparisons, t-test. (C) Kaplan-Meier plot of overall survival of cases separated by 
anatomical location, p value calculated by the log-rank test (n=811). (D) Anatomical 
location of all cases separated by histone mutation (top, n=441) and histone wild-
type (bottom, n=314). Left – sagittal section showing internal structures; right – 
external view highlighting cerebral lobes. Blue = H3.3G34R/V; green = H3.3K27M; 
dark green = H3.1K27M. Radius of circle is proportional to the number of cases. 
Lighter shaded circles represent a non-specific designation of hemispheric, midline 
or brainstem. (E) Boxplot showing age at diagnosis of included cases, separated by 
histone mutation (n=753). The thick line within the box is the median, the lower and 
upper limits of the boxes represent the first and third quartiles, and the whiskers 1.5x 
the interquartile range. *** adjusted p<0.0001 for all pairwise comparisons, t-test. (F) 
Kaplan-Meier plot of overall survival of cases separated by histone mutation, p value 
calculated by the log-rank test (n=693). See also Figure S1 and Table S1. 
 
Figure 2 – Methylation-based subclassification of pHGG/DIPG. (A) Unsupervised 
hierarchical clustering and heatmap representation of beta values for 441 samples 
profiled on the Illumina 450k BeadArray platform (red, high; blue, low). Samples are 
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arranged in columns clustered by most variable 1,381 classifier probes. Age at 
diagnosis is provided below. Clinicopathological and molecular annotations are 
provided as bars according to the included key. (B) Anatomical location of 
methylation-defined PXA-like (n=43) and LGG-like (n=27) cases. Left – sagittal 
section showing internal structures; right – external view highlighting cerebral lobes. 
Dark gold = PXA-like; tan = LGG-like. Radius of circle is proportional to the number 
of cases. Lighter shaded circles represent a non-specific designation of hemispheric, 
midline or brainstem. (C) Boxplot showing age at diagnosis of included cases, 
separated by simplified methylation subclass (n=440). The thick line within the box is 
the median, the lower and upper limits of the boxes represent the first and third 
quartiles, and the whiskers 1.5x the interquartile range. *** adjusted p<0.0001 for all 
GBM_G34 pairwise comparisons, t-test. ** adjusted p<0.01 for LGG-like versus wild-
type, t-test. (D) Kaplan-Meier plot of overall survival of cases separated by simplified 
methylation subclass, p value calculated by the log-rank test (n=307). See also 
Figure S2 and Table S2. 
 
Figure 3 – DNA copy number aberrations in pHGG/DIPG. (A) Heatmap 
representation of segmented DNA copy number for 834 pHGG/DIPG profiled across 
one or more of seven different platforms (dark red, amplification; red, gain; dark blue, 
deletion; blue, loss). Samples are arranged in columns clustered by gene-level data 
across the whole genome. Age at diagnosis is provided below. Clinicopathological 
and molecular annotations are provided as bars according to the included key. (B, C) 
Barplot of all recurrent focal amplifications (B) and deletions (C) across all 834 cases, 
in order of frequency, and colored independently by both anatomical location and 
histone mutation. See also Figure S3 and Table S3. 
 
Figure 4 – Subgroup-specific copy number changes in pHGG/DIPG. (A) Heatmap 
representation of segmented DNA copy number for 705 pHGG/DIPG separated for 
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known histone mutation subgroup (dark red, amplification; red, gain; dark blue, 
deletion; blue, loss). Samples are arranged in columns clustered by gene-level data 
across the whole genome. Clinicopathological and molecular annotations are 
provided as bars according to the included key. (B) GISTIC analysis of focal 
amplifications and deletions for histone mutation subgroups. Log10 values are plotted 
across the genome for both amplifications (dark red) and deletions (dark blue), with 
significantly enriched events labelled by likely driver genes. Subgroup-specific genes 
are highlighted by the appropriate color. (C) Barplot of frequency of whole 
chromosomal arm gains (red) and losses (blue) for each subgroup. Significantly 
enriched alterations (p<0.0001, Fishers exact test) are labelled, with subgroup-
specific arm changes highlighted by the appropriate color. See also Figure S4 and 
Table S4. 
 
Figure 5 – Alterations targeting FBXW7 in H3.3G34R/V pHGG and TOP3A in 
H3.3K27M DIPG. (A) Segmented exon-level DNA copy number heatmaps for 4q loss 
in H3.3G34R/V tumors (dark red, amplification; red, gain; dark blue, deletion; blue, 
loss; n=28). An ideogram of chromosome 4 is provided indicating enlarged genome 
browser view and genes within common regions targeted across samples (grey). 
Clinicopathological and molecular annotations are provided as bars according to the 
included key. (B) Cartoon representation of amino acid position for four somatic 
mutations found in FBXW7, colored by annotated functional domains and numbers 
provided for recurrent variants. (C) Boxplots representing gene expression 
differences between FBXW7 lost/mutated cases (blue) and those with normal 
copy/wild-type (grey) in three independent gene expression platform datasets. The 
thick line within the box is the median, the lower and upper limits of the boxes 
represent the first and third quartiles, and the whiskers 1.5x the interquartile range. 
(D) Segmented exon-level DNA copy number heatmaps for 17p11.2 amplification in 
predominantly H3.3K27M DIPG (dark red, amplification; red, gain; dark blue, 
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deletion; blue, loss; n=17). Chromosome 17 ideogram is provided indicating enlarged 
genome browser view and genes within common regions targeted across samples 
(grey). Clinicopathological and molecular annotations are provided as bars according 
to the included key. (E) Sequencing coverage (top) and log2 ratio plot (bottom) for 
chromosomes 7, 17 and 20 for two cases, showing complex intra- or inter-
chromosomal rearrangements leading to specific copy number amplification of 
TOP3A. (F) Boxplots representing gene expression differences between TOP3A 
amplified cases (red) and those with normal copy (grey) in three independent gene 
expression platform datasets. The thick line within the box is the median, the lower 
and upper limits of the boxes represent the first and third quartiles, and the whiskers 
1.5x the interquartile range. See also Figure S5 and Table S5.  
 
Figure 6 – Somatic mutations in pHGG/DIPG. (A) Oncoprint representation of an 
integrated annotation of somatic mutations and DNA copy number changes for the 
30 most frequently altered genes in 326 pHGG/DIPG (n6, frequency barplot on the 
right). Selected common fusion events are also shown where available. Samples are 
arranged in columns with genes labelled along rows. Age at diagnosis is provided 
below. Underneath, barplots are provided on a log10 scale for numbers of copy 
number aberrations and somatic mutations per case. Clinicopathological and 
molecular annotations are provided as bars according to the included key. (B) 
Barplot of all recurrent somatic mutations across all 326 cases, in order of frequency, 
and colored independently by both anatomical location and histone mutation. See 
also Figure S6 and Table S6. 
 
Figure 7 – Integrated pathway analysis of pHGG/DIPG. (A) Oncoprint-style 
representation of an integrated annotation of somatic mutations and DNA copy 
number changes in one or more of nine commonly targeted pathways in 326 
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pHGG/DIPG (n6, frequency barplot on the right). Samples are arranged in columns 
with pathways labelled along rows. Clinicopathological and molecular annotations 
are provided as bars according to the included key. (B) Pathway enrichment analysis 
of pHGG/DIPG subgroups. Distinct pathways and biological processes between the 
subgroups are colored appropriately (FDR q<0.01). Nodes represent enriched gene 
sets, which are grouped and annotated by their similarity according to related gene 
sets. Node size is proportional to the total number of genes within each gene set. 
The illustrated network map was simplified by manual curation to remove general 
and uninformative sub-networks. See also Figure S7 and Table S7.  
 
Figure 8 – Integrated analysis of H3/IDH1 wild-type pHGG/DIPG. (A) t-statistic 
based stochastic neighbor embedding (t-SNE) projection of the combined 450k 
methylation dataset (n=441). The first three projections are plotted in the x, y and z 
axes, with samples represented by dots colored by histone H3G34 (blue), H3K27 
(green), IDH1 (red), PXA-like (dark gold), LGG-like (tan) and ‘others’ (grey). (B) K-
means consensus clustering on the H3/IDH1 wild-type cases highlights 3 stable 
clusters (left – black/brown (WT-A), grey/pink (WT-B) and dark cyan (WT-C)) as the 
most robust subdivision of the data (right, area under the curve analysis for different 
cluster numbers). (C) Unsupervised hierarchical clustering and attendant heatmap of 
the H3/IDH1 wild-type cases (n=219). Samples are arranged in columns clustered by 
the most variable 1,521 classifier probes. Age at diagnosis is provided below. 
Clinicopathological and molecular annotations are provided as bars according to the 
included key. (D) Oncoprint representation of an integrated annotation of somatic 
mutations and DNA copy number changes for the H3/IDH1 wild-type cases (n=50). 
Samples are arranged in columns with genes labelled along rows. Age at diagnosis 
is provided below. Clinicopathological and molecular annotations are provided as 
bars according to the included key. (E) Boxplot showing age at diagnosis of H3/IDH1 
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wild-type subgroups, separated by anatomical location (n=190). The thick line within 
the box is the median, the lower and upper limits of the boxes represent the first and 
third quartiles, and the whiskers 1.5x the interquartile range. (F) Kaplan-Meier plot of 
overall survival of H3/IDH1 wild-type subgroups separated by anatomical location, p 
value calculated by the log-rank test (n=150). See also Figure S8 and Table S8. 
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STAR Methods 
CONTACT FOR REAGENT AND RESOURCE SHARING  
Further information and requests for resources and reagents should be directed to 
and will be fulfilled by the Lead Contact, Chris Jones (chris.jones@icr.ac.uk).  
 
EXPERIMENTAL MODEL AND SUBJECT DETAILS  
Patient samples  
All new patient material was collected after informed consent and subject to local 
research ethics committee approval. We collated and profiled 157 unpublished cases 
of HGG in children and young adults up to the age of 30 years at diagnosis obtained 
from the Royal Marsden, St Georges and Kings College Hospitals, (n=39, all London, 
UK), Chinese University of Hong Kong (n=24, Hong Kong, China), Qilu University 
Hospital (n=23, Jinan, China), Farhad Hatched Hospital (n=14, Sousse, Tunisia), 
Federal University of São Paolo (n=14, São Paulo, Brazil), Morozov Children’s and 
Dmitri Rogachev Hospitals (n=12, Moscow, Russia), Queensland Children’s Tumor 
Bank (n=8, Brisbane, Australia), Hospital San Joan de Déu (n=8, Barcelona, Spain), 
City Hospital #31 (n=6, St Petersburg, Russia), Barretos Cancer Hospital (n=4, 
Barretos, Brazil), Centre Hospitalier Régional et Universitaire Hautepierre (n=3, 
Strasbourg, France), and Our Lady Children’s Hospital Crumlin (n=2, Dublin, 
Ireland). A full description of the samples included are provided in Table S1. 
 
METHOD DETAILS  
Nucleic acid extraction 
DNA was extracted from frozen tissue by homogenisation prior to following the 
DNeasy Blood & Tissue kit protocol (Qiagen, Crawley, UK). DNA was extracted from 
formalin-fixed, paraffin-embedded (FFPE) pathology blocks after manual 
macrodissection using the QIAamp DNA FFPE tissue kit protocol (Qiagen). Matched 
normal DNA was extracted from blood samples using the DNeasy Blood & Tissue kit 
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(Qiagen, Crawley, UK). Concentrations were measured using a Qubit fluorometer 
(Life Technologies, Paisley, UK). RNA was extracted by following the RNeasy Mini 
Kit protocol (Qiagen), and quantified on a 2100 Bioanalyzer (Agilent Technologies). 
 
Sanger sequencing of H3F3A / HIST1H3B 
PCR for H3F3A and HIST1H3B was carried out using primers obtained from Life 
Technologies (Paisley, UK). Products were purified using the QIAquick PCR 
purification kit (Qiagen), subjected to bidirectional sequencing using BigDye 
Terminator mix 3.1 (Applied Biosystems, Foster City, CA, USA), with capillary 
sequencing was done on an ABI 3100 genetic analyzer (Applied Biosystems, Foster 
City, CA, USA). Sequences were analysed using Mutation Surveyor (SoftGenetics, 
PN, USA) and manually with 4Peaks (Nucleobytes, Aalsmeer, Netherlands).  
 
Methylation profiling 
50-500 ng DNA was bisulphite-modified and analyzed for genome-wide methylation 
patterns using the Illumina HumanMethylation450 BeadArray (450k) platform at 
either the DKFZ or the University College London Genomics Centre, according the 
manufacturer’s instructions. All samples were checked for expected and unexpected 
genotype matches by pairwise correlation of the 65 genotyping probes on the 450k 
array. 
 
Exome and RNA sequencing  
50-500 ng DNA was sequenced at the Tumor Profiling Unit, ICR, London, UK using 
the SureSelect Human All Exon capture sets V4 or V5  (Agilent, Santa Clara, CA, 
USA), and paired-end-sequenced on an Illumina HiSeq2000 (Illumina, San Diego, 
CA, USA) with a 100 bp read length. Coverage ranged from 29-295x (median=105x). 
RNA was sequenced at the ICR Tumor Profiling Unit after SureSelect RNA capture 
on an Illumina HiSeq2500 with a 125 bp read length.  
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QUANTIFICATION AND STATISTICAL ANALYSIS  
Published data sources 
These data were combined with those obtained directly from the authors or from 
public data repositories representing 20 published studies (Barrow et al., 2011; Bax 
et al., 2010; Buczkowicz et al., 2014; Carvalho et al., 2014; Castel et al., 2015; 
Fontebasso et al., 2014; Fontebasso et al., 2013; Grasso et al., 2015; International 
Cancer Genome Consortium PedBrain Tumor, 2016; Khuong-Quang et al., 2012; 
Korshunov et al., 2015; Paugh et al., 2011; Paugh et al., 2010; Puget et al., 2012; 
Schwartzentruber et al., 2012; Sturm et al., 2012; Taylor et al., 2014a; Wu et al., 
2012; Wu et al., 2014; Zarghooni et al., 2010) with the following accession numbers: 
EGA - EGAS00001000226, EGAS0000100192, EGAS00001000575, 
EGAS00001000720, EGAS00001001139; the Gene Expression Omnibus 
(www.ncbi.nlm.nih.gov/geo/) - GSE19578, GSE26576,  GSE21420, GSE34824, 
GSE36245, GSE36278 GSE50022, GSE50021, GSE50024, GSE55712; 
ArrayExpress - E-TABM-857, E-TABM-1107. The full cohort included a total of 1254 
molecular profiles from 955 samples across 12 platforms, which after quality control 
and manual annotation to remove duplicates, and supplemented with targeted 
sequencing of an additional 158 cases, resulted in a total dataset comprised of 1067 
individual patients. The full dataset comprises genomic profiles from DNA copy 
number arrays (Agilent 44K, n=127; Affymetrix 500K, n=100; Affymetrix SNP6.0, 
n=78; 32k BAC, n=61), Illumina 450k methylation arrays (n=441), whole exome 
(n=254), genome (n=125), targeted (n=212) and RNA sequencing (n=82), as well as 
gene expression from Affymetrix U133Plus2 (n=102) and Agilent WG2.5 (n=67) 
platforms.  
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DNA copy number 
DNA copy number data was obtained as array CGH (Agilent 44k and 32K BAC), 
SNP arrays (Affymetrix 500k and SNP6.0), 450k methylation arrays (Illumina) and/or 
sequencing data (whole genome and exome). Two color aCGH data was read and 
normalized using the R packages limma and marray. Log intensity data from 
Affymetrix SNP arrays was derived using the aroma.affymetrix  and aroma.cn 
package. Combined log2 intensity data from Illumina 450K methylation arrays was 
processed using the R packages minfi and conumee. For sequenced samples, 
coverage of aligned reads was binned into known genes and exons with BEDTools 
and log2 ratios of median coverage in tumor and normal sequences were processed 
with in-house scripts. To combine copy number platforms, median log2 ratios were 
recovered within all known genes and exons and normalized such that the median 
displacement of X in male:female comparisons was rescaled to an average of -1. 
Exon-level median log ratios and smoothed values were then combined across 
platforms and thresholded to call gains and losses above and below log2 ratios of 
±0.3 with a contig of ~1MB and amplifications and deletions above and below a 
threshold of ±1.5 with a minimum of 3 contiguous exons.  
 
CBS binary segmentation from the DNAcopy package was applied to each dataset to 
provide smoothed log2 ratios. Genes within common CNVs in normal individuals 
were excluded from further analysis with reference to the CNV map of the human 
genome. DNA copy number data was clustered based upon categorical states (deep 
deletion, loss, no change, gain and amplification) based upon the Euclidean distance 
method with a Ward algorithm. Gains and losses in chromosomal arms were called 
based upon contiguous regions covering more than one third of the exonic regions 
within each arm. For regions of focal copy number change cases carrying copy 
number alterations were ranked according to the length of the largest CNA in each 
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case and are plotted as heatmaps aligned to precise genomic coordinates alongside 
genomic tracks based upon hg19 made with the R package gviz.  Minimal regions 
of copy number alteration were assigned based on the frequency of categorical 
states within each region. Focal amplifications and deletions were identified in CBS 
segmented data using the GISTIC algorithm in MATLAB on the exon-level data, with 
thresholds for gain and loss of 0.3 and gene-level filters to remove regions of 
common copy number variation in normal individuals based on the CNV map of the 
human genome. 
 
DNA methylation 
Methylation data from the Illumina Infinium HumanMethylation450 BeadChip was 
preprocessed using the minfi package in R. DNA copy number was recovered from 
combined intensities using the conumee package with reference to methylation 
profiles from normal individuals provided in the CopyNumber450kData package. 
We have used the Heidelberg brain tumor classifier (molecularneuropathology.org) to 
assign subtype scores for each tumor compared to 91 different brain tumor entities 
using a training set built from more than 2000 tumors implemented in the MNP R 
package. Simplified methylation subgroup assignments were then made to 
incorporate cases carrying G34R/V or K27M mutations in H3 histones, IDH1 
mutation at R132, low grade glioma-like profiles (predominantly diffuse infantile 
ganglioglioma and pilocytic astrocytoma) and those similar to pleomorphic 
xanthoastrocytoma (PXA). Wild-type HGG encompassed many other methylation 
subgroups and were simply assigned by exclusion with the groups above. Clustering 
of beta values from methylation arrays was performed using the 10K probeset from 
the Heidelberg classifier based upon Euclidean distance with a ward algorithm. 
Methylation heatmaps show only the most variable probes of the classifier between 
simplified methylation subgroups. Overall methylation was calculated as the mean of 
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the 10K classifier probeset for each subgroup and MGMT promoter methylation was 
calculated based upon the MGMT-SPT27 model implemented in the MNP package. t- 
stochastic neighbor embedding (tSNE) was used to project the methylation clustering 
in three dimensions using the Rtsne package. A Pearson correlation matrix of the 
10K probeset was subjected to tSNE using a theta value of zero over 10,000 
iterations as previously described and plotted using the rgl package. 
 
mRNA expression 
Gene expression data was obtained from Agilent WG2.5, Affymetrix U133Plus2.0 or 
RNA sequencing platform. Gene expression was processed from two color Agilent 
microarrays using the R packages marray and limma and from single channel 
Affymetrix arrays using the affy package. Differential expression was assigned for 
microarray data using the limma package based upon a false discovery rate of 5%. 
RNASeq was aligned with Bowtie2 and TopHat and summarized as gene level 
fragments per kilobase per million reads sequenced using BEDTools and 
cufflinks/cuffnorm. Following rlog transformation and normalization differential 
expression was assigned with DESeq.2. Known Ensembl genes were further filtered 
to remove low abundance genes in all three datasets whose maximal expression 
was within the lowest 20% of all expression values based upon probe intensities or 
read depth. Replicate probes/features for each gene were removed by selecting 
those with the greatest median absolute deviation (MAD) in each dataset. Following 
centering within each dataset, log-transformed expression measures were combined 
and further normalized using pairwise loess normalization. Gene Set enrichment 
analysis was performed using the GSEA java application based upon pairwise 
comparisons of the major subgroups in the merged dataset. Heatmaps of gene 
expression across chromosomal arms were made using centered expression values 
rescaled across each chromosomal arm based upon the median absolute deviation 
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of each probe. Differential expression analysis of TOP3A and FBXW7 was based on 
a Mann-Whitney U test of centred expression values between cases with and without 
losses and amplifications respectively in each case. 
 
Sequence analysis 
Sequencing data was available as whole genome and/or whole exome 
(predominantly using Agilent’s SureSelect whole exome capture sets v4 and v5) 
Short read sequences from whole exome or whole genome sequencing were aligned 
to the hg19 assembly of the human genome using bwa. Following duplicate removal 
with Picard tools variants were called using the Genome Analysis toolkit according to 
standard Best Practices (Broad) including local re-alignment around Indels, 
downsampling and variant calling with the Unified Genotyper. Variants were 
annotated with the variant Effect predictor v74 from Ensembl tools and ANNOVAR to 
include annotations for variant allele frequency in 1000 genomes dbSNP v132 and 
the ExAc database as well as functional annotation tools SIFT and Polyphen). Depth 
of coverage varied from 16-295x (median 88x), with the greatest variation 
unsurprisingly in the exome data  (whole genome range 50-150x, median=85x). 
Somatic variants were identified in regions covered by at least 10 reads in normal 
and tumor sequences carrying at least 3 variant reads in the tumor and less than 2 in 
normal sequences. Hotspot TERT promoter mutations C228T and C250T were 
incidentally captured by the various exome platforms as they are located only 114 
and 146 bp upstream of the translation start site, and were called even if only 
covered by a few reads. Mutation signatures were ascertained by grouping somatic 
substitutions on the basis of their 3′ and 5′ bases into 96 possible trinucleotide 
categories. 
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Candidate fusion gene nomination 
Structural variants were called from whole genome data using Breakdancer 
(breakdancer.sourceforge.net) filtered to remove commonly multi-mapped regions to 
identify somatic breakpoints separated by a minimum of 10 kbp involving at least one 
Ensembl gene. Fusion transcripts were detected from RNAseq data using 
chimerascan version 0.4.5a filtered to remove common false positives. To minimize 
unverified false positives, reporting of nominated fusions was restricted to genes 
within the core functional pathways and processes identified through integrated DNA 
copy number and somatic variant calling.  
 
Inferred tumor purity 
We used determined the somatic allele-specific copy number profiles using read 
depth from whole genome / exome sequencing, and used ASCAT (rick.ac.uk/peter-
van-loo/software/ASCAT) to provide for an estimate of the non-neoplastic cell 
contamination of the sample as well as the overall ploidy of the tumor. Values ranged 
from 36-100%, with a median of 83%.  
 
Integrated analysis of driver events 
Somatic non-synonymous coding mutations were filtered to remove common 
passenger mutations, polymorphisms and false positives in exome sequencing. Data 
were integrated with focal DNA copy number calls by GISTIC to provide gene-level 
binary alteration calls which were further selected for putative drive status on the 
basis of functional annotation. Oncoprint representations of integrated mutations, 
gene-level copy number alterations and fusion events were made using the online 
tool available at cBioportal (cbioportal.org). For the most commonly mutated genes 
mutations were mapped to the canonical transcript and plotted according to their 
predicted protein position using the Protein Painter (pecan.stjude.org). Integrated 
views of copy number alterations, structural variants and somatic mutations were 
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made using CIRCOS (circos.ca) and rearrangements within TOP3A amplified 
regions in whole genome sequenced cases were identified using Breakdancer and 
aligned with copy number breakpoints in R.  
 
Pathway analysis 
Pathway assignments were made for all genes carrying copy number alterations, 
structural variations or somatic mutations based on pathways in the MSigDB 
molecular signatures databases (Broad) as well as Gene ontologies for Biological 
Processes and Molecular Functions (Gene Ontology consortium) and canonical 
pathways from KEGG, NetPath and Reactome. Genes within known CNVs and 
common false positives in exomic sequencing were excluded with reference to large 
scale genome profiling studies (CNVmap, ExAc, BCBio) Pathway analysis of genes 
carrying mutations, gene fusions and copy number aberrations was based on the 
pathways defined by these combined databases and subjected to enrichment 
analysis using the enrichmentMap module within CytoScape.  
 
Statistical analysis 
Statistical analysis was carried out using R 3.3.1 (www.r-project.org). Categorical 
comparisons of counts were carried out using Fishers exact test, comparisons 
between groups of continuous variables employed Student’s t-test, Wilcoxon signed 
–rank test, ANOVA or Mann-Whitney U test. Differences in survival were analysed by 
the Kaplan-Meier method and significance determined by the log-rank test. All tests 
were two-sided and a p value of less than 0.05 was considered significant. Multiple 
testing was accounted for using false discovery rate q values or the Bonferroni 
adjustment. 
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DATA AND SOFTWARE AVAILABILITY  
All newly generated data have been deposited in the European Genome-phenome 
Archive (www.ebi.ac.uk/ega) with accession number EGAS00001002314 
(sequencing) or ArrayExpress (www.ebi.ac.uk/arrayexpress/) with accession number 
E-MTAB-5528 (450k methylation).  
 
ADDITIONAL RESOURCES  
Processed copy number profiles are hosted as a disease-specific project within the 
Progenetix framework for annotated genomic analyses (dipg.progenetix.org) (Cai et 
al., 2014), and represented in the arrayMap resource (arraymap.org) (Cai et al., 
2012). Curated gene-level copy number and mutation data are provided as part of 
the pediatric-specific implementation of the cBioPortal genomic data visualisation 
portal (pedcbioportal.org). Newly-generated raw data files are housed alongside 
published datasets made available to the Cavatica NIH-integrated cloud platform 
(www.cavatica.org). 
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Supplemental Tables 
Table S1, related to Figure 1. Clinicopathological and molecular subgroups of 
pHGG/DIPG. 
 
Table S2, related to Figure 2. Methylation-based subclassification of pHGG/DIPG.  
 
Table S3, related to Figure 3. DNA copy number aberrations in pHGG/DIPG. 
 
Table S4, related to Figure 4. Subgroup-specific copy number changes in 
pHGG/DIPG.  
 
Table S5, related to Figure 5. Novel alterations targeting FBXW7 in H3.3G34R/V 
pHGG and TOP3A in H3.3K27M DIPG.  
 
Table S6, related to Figure 6. Somatic mutations in pHGG/DIPG.  
 
Table S7, related to Figure 7. Integrated pathway analysis of pHGG/DIPG. 
 
Table S8, related to Figure 8. Integrated analysis of H3/IDH1 wild-type pHGG/DIPG.  
 
 
 
 KEY RESOURCES TABLE 
REAGENT or RESOURCE SOURCE IDENTIFIER 
Critical Commercial Assays 
DNeasy blood & tissue kit Qiagen 69504 
QIAmp DNA FFPE tissue kit Qiagen 56404 
RNeasy mini kit Qiagen 74104 
QIAquick PCR purification kit Qiagen 28104 
BigDye terminator v3.1 mix Thermo Fisher 4337455 
SureSelect Human All Exon capture set V4 
SureSelect Human All Exon capture set V5 
Agilent 5190-4666 
5190-6208 
SureSelect RNA Capture, 0.5-2.9Mb Agilent 5190-4944 
 
Deposited Data 
Exome and RNA sequencing of new samples This paper EGA: 
EGAS00001002314 
Illumina methylation BeadChip profiling of new samples This paper ArrayExpress:  
E-MTAB-5528 
Sequencing and methylation data This paper cavatica.org 
 
Oligonucleotides 
Primer: H3F3A_forward 
TGGCTCGTACAAAGCAGACT 
This paper N/A 
Primer: H3F3A_reverse 
ATATGGATACATACAAGAGAGACT 
This paper N/A 
Primer: HIST1H3B_forward 
GGGCAGGAGCCTCTCTTAAT 
This paper N/A 
Primer: HIST1H3B _ reverse 
ACCAAGTAGGCCTCACAAGC 
This paper N/A 
 
Software and Algorithms 
Mutation Surveyor SoftGenetics softgenetics.com/mu
tationSurveyor.php 
4Peaks Nucleobytes http://nucleobytes.co
m/4peaks/ 
limma BioConductor bioconductor.org/pac
kages/release/bioc/h
tml/limma.html 
marray BioConductor bioconductor.org/pac
kages/release/bioc/h
tml/marray.html 
aroma.affymetrix The Comprehensive R 
Archive Network 
cran.rstudio.com/we
b/packages/aroma.af
fymetrix/index.html 
aroma.cn The Comprehensive R 
Archive Network 
cran.r-
project.org/web/pack
ages/aroma.cn/index
.html 
minfi BioConductor bioconductor.org/pac
kages/release/bioc/h
tml/minfi.html 
Key Resource Table
 conumee BioConductor bioconductor.org/pac
kages/release/bioc/h
tml/conumee.html 
BEDtools University of Utah github.com/arq5x/be
dtools2 
DNAcopy BioConductor bioconductor.org/pac
kages/release/bioc/h
tml/DNAcopy.html 
gviz BioConductor bioconductor.org/pac
kages/release/bioc/h
tml/Gviz.html 
GISTIC Broad Institute oftware.broadinstitut
e.org/software/cprg/
?q=node/31 
CopyNumber450kData BioConductor bioconductor.org/pac
kages/release/data/e
xperiment/html/Copy
Number450kData.ht
ml 
MNP DKFZ Heidelberg molecularneuropath
ology.org/mnp 
tSNE The Comprehensive R 
Archive Network 
cran.r-
project.org/web/pack
ages/Rtsne/index.ht
ml 
rgl The Comprehensive R 
Archive Network 
cran.r-
project.org/web/pack
ages/rgl/index.html 
affy BioConductor bioconductor.org/pac
kages/release/bioc/h
tml/affy.html 
Bowtie2 Johns Hopkins 
University 
bowtie-
bio.sourceforge.net/
bowtie2/index.shtml 
TopHat Johns Hopkins 
University 
ccb.jhu.edu/software
/tophat/index.shtml 
cufflinks University of 
Washington 
ole-trapnell-
lab.github.io/cufflinks
/cufflinks/ 
DESeq2 BioConductor bioconductor.org/pac
kages/release/bioc/h
tml/DESeq2.html 
Gene Set Enrichment Analysis Broad Institute http://software.broadi
nstitute.org/gsea 
bwa Sanger Institute http://bio-
bwa.sourceforge.net/ 
Genome Analysis Toolkit Broad Institute oftware.broadinstitut
e.org/gatk/ 
Variant Effect predictor Ensembl tools ensembl.org/info/doc
s/variation/vep 
ANNOVAR Children’s Hospital of 
Philadelphia 
annovar.openbioinfo
rmatics.org/en/latest/ 
 ExAc Broad Institute exac.broadinstitute.o
rg/ 
BCBio Harvard TH Chan bcb.io/ 
SIFT J Craig Venter 
Institute 
sift.jcvi.org 
PolyPhen Harvard genetics.bwh.harvar
d.edu/pph2 
ChimeraScan University of Michigan omictools.com/chime
rascan-tool 
Breakdancer Washington University 
of St Louis 
breakdancer.sourcef
orge.net 
ASCAT Francis Crick Institute rick.ac.uk/peter-van-
loo/software/ASCAT 
Oncoprinter Memorial Sloan 
Kettering 
cbioportal.org/oncop
rinter.jsp 
ProteinPaint St Jude pecan.stjude.org/#/p
roteinpaint 
Circos Michael Smith 
Genome Sciences 
Center 
circos.ca 
MSigDB Broad Institute http://software.broadi
nstitute.org/gsea/msi
gdb 
CytoScape National Institute of 
General Medical 
Sciences 
cytoscape.org 
R The Comprehensive R 
Archive Network 
r-project.org 
 
Other 
Processed DNA copy number profiles This paper and cited 
sources 
dipg.progenetix.org 
arraymap.org 
Integrated mutation, copy number, expression and 
methylation data 
This paper and cited 
sources 
pedcbioportal.org 
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Figure S1 (related to Figure 1) – Clinicopathological and molecular subgroups of pHGG/DIPG. 
(A) Venn diagram showing overlapping molecular data for the cohort. (B) Anatomical location 
of all cases separated by age at diagnosis <1 year (n=40). Radius of circle is proportional to 
the number of cases. Left – sagittal section showing internal structures; right – external view 
highlighting cerebral lobes. Orange = infant. Lighter shaded circles represent a non-specific 
designation of hemispheric, midline or brainstem. (C) Kaplan-Meier plot of overall survival of 
cases separated by age at diagnosis <1 year, between 1-3 years, and >3 years of age, p value 
calculated by the log-rank test (n=818). (D-F) Kaplan-Meier plot of overall survival of cases 
separated by histone mutation in (D) hemispheric (n=220), (E) midline (n=131), (F) brainstem 
locations (n=242), p value calculated by the log-rank test. (G) Anatomical location of all cases 
separated by BRAF V600E mutation (n=32, wild-types not shown). Radius of circle is 
proportional to the number of cases. Left – sagittal section showing internal structures; right – 
external view highlighting cerebral lobes. Gold = BRAF V600E. Lighter shaded circles 
represent a non-specific designation of hemispheric, midline or brainstem. (H) Boxplot 
showing age at diagnosis of included cases, separated by BRAF V600E mutation (n=553). 
The lower and upper limits of the boxes represent the first and third quartiles, and the whiskers 
1.5x the interquartile range. (I) Kaplan-Meier plot of overall survival of cases separated by 
BRAF V600E, p value calculated by the log-rank test (n=416). (J) Anatomical location of all 
cases separated by IDH1 R132 mutations (n=40, wild-types not shown). Radius of circle is 
proportional to the number of cases. Left – sagittal section showing internal structures; right – 
external view highlighting cerebral lobes. Red = IDH R132. Lighter shaded circles represent a 
non-specific designation of hemispheric, midline or brainstem. (K) Boxplot showing age at 
diagnosis of included cases, separated by IDH1 R132 mutations (n=672). The thick line within 
the box is the median, the lower and upper limits of the boxes represent the first and third 
quartiles, and the whiskers 1.5x the interquartile range. *** p<0.0001, t-test. (L) Kaplan-Meier 
plot of overall survival of cases separated by IDH1 R132 mutations, p value calculated by the 
log-rank test (n=551).  
 
  
Figure S2 (related to Figure 2) – Methylation-based subclassification of pHGG/DIPG. (A) 
Boxplot of Heidelberg brain tumor subclassifier scores for pediatric HGG in the present study 
(solid circles, n=441) assigned to one of six HGG subgroups defined by a reference set (open 
circles). The thick line within the box is the median, the lower and upper limits of the boxes 
represent the first and third quartiles, and the whiskers 1.5x the interquartile range. H3 G34R/V 
– blue; H3 K27M – green; IDH1 – red; PXA-like – gold; LGG-like – tan; HGG WT – grey. (B) 
Barplots of number of cases with methylated MGMT promoter, subdivided by methylation 
subgroup (n=366). (C) Boxplots of mean methylation beta-values for cases subdivided by 
methylation subgroup (n=441). The thick line within the box is the median, the lower and upper 
limits of the boxes represent the first and third quartiles, and the whiskers 1.5x the interquartile 
range. *** p<0.001, ** p<0.01, *p<0.05 versus rest, t-test.  
 
 
  
  
  
  
  
  
  
  
Figure S3 (related to Figure 3) – DNA copy number aberrations in pHGG/DIPG. (A) DNA copy 
neutral cases. (a) Anatomical location (n=147). Radius of circle is proportional to the number 
of cases. Left – sagittal section showing internal structures; right – external view highlighting 
cerebral lobes. Pale grey = copy neutral cases. Lighter shaded circles represent a non-specific 
designation of hemispheric, midline or brainstem. (b) Boxplot showing age at diagnosis of 
included cases, separated by DNA copy neutral cases (n=798). The thick line within the box 
is the median, the lower and upper limits of the boxes represent the first and third quartiles, 
and the whiskers 1.5x the interquartile range. *** p<0.0001, t-test. (c) Kaplan-Meier plot of 
overall survival of cases separated by DNA copy neutral cases, p value calculated by the log-
rank test (n=638). (d) Venn diagrams showing platform distribution of copy neutral (left, n=147) 
and other cases (right, n=687). (B-G) Recurrent copy number changes. (a) Segmented exon-
level DNA copy number heatmaps for (B) 17p loss (n=156), (C) 9q gain (n=108), (D) 2p24 
amplification (n=42), (E) 4q12 amplification (n=77), (F) chromosome 7 amplifications (n=59), 
(G) 9p21 deletion (n=102). Dark red, amplification; red, gain; dark blue, deletion; blue, loss. 
Chromosomal ideograms are provided indicating enlarged genome browser view and genes 
within common regions targeted across samples (grey). Clinicopathological and molecular 
annotations are provided as bars according to the included key. (B-F) (b) Kaplan-Meier plot of 
overall survival of subgroups of cases separated by indicated DNA copy number change, p 
value calculated by the log-rank test. (G) 9p loss. (b) Anatomical location (n=115). Radius of 
circle is proportional to the number of cases. Left – sagittal section showing internal structures; 
right – external view highlighting cerebral lobes. Dark blue = 9p loss cases. Lighter shaded 
circles represent a non-specific designation of hemispheric, midline or brainstem. (c) Boxplot 
showing age at diagnosis of included cases, separated by 9p loss cases (n=798). The thick 
line within the box is the median, the lower and upper limits of the boxes represent the first 
and third quartiles, and the whiskers 1.5x the interquartile range. *** p<0.0001, t-test. (d,e) 
Kaplan-Meier plot of overall survival of cases separated by 9p loss cases, p value calculated 
by the log-rank test (n=659). 
  

   

Figure S4 (related to Figure 4) – Subgroup-specific copy number changes in pHGG/DIPG. 
(A) GISTIC and frequency barplots for whole chromosomal arm changes for (a) histone wild-
type cases and (b) H3.3K27M cases subdivided by anatomical location. Log10 values for 
GISTIC are plotted across the genome for both amplifications (dark red) and deletions (dark 
blue), with significantly enriched events labelled by likely driver genes. Subgroup-specific 
genes are highlighted by the appropriate color, as are significantly enriched whole arm 
alterations (p<0.0001, Fishers exact test). (B) Histone wild-type cases. (b) GISTIC and 
frequency barplots for whole chromosomal arm changes subdivided by simplified methylation 
subclass. Log10 values for GISTIC are plotted across the genome for both amplifications (dark 
red) and deletions (dark blue), with significantly enriched events labelled by likely driver genes. 
Subgroup-specific genes are highlighted by the appropriate color, as are significantly enriched 
whole arm alterations (p<0.0001, Fishers exact test). (b) Segmented exon-level DNA copy 
number heatmaps for 1q loss in PXA-like cases (dark red, amplification; red, gain; dark blue, 
deletion; blue, loss; n=5). Chromosomal ideograms are provided indicating enlarged genome 
browser view and genes within common regions targeted across samples (grey). 
Clinicopathological and molecular annotations are provided as bars according to the included 
key. (c) Kaplan-Meier plot of overall survival of subgroups of cases separated by indicated 
DNA copy number change in PXA-like cases (n=35), p value calculated by the log-rank test. 
(C) Copy number losses in H3.3G34R/V cases. (a) 3q loss (n=29). (b) 5q loss (n=18). (c) 18q 
loss (n=20). Segmented exon-level DNA copy number heatmaps for losses in H3.3G34R/V 
cases (dark red, amplification; red, gain; dark blue, deletion; blue, loss). Chromosomal 
ideograms are provided indicating enlarged genome browser view and genes within common 
regions targeted across samples (grey). Clinicopathological and molecular annotations are 
provided as bars according to the included key. 
 
 
  
  
Figure S5 (related to Figure 5) – Alterations targeting FBXW7 in H3.3G34R/V pHGG and 
TOP3A in H3.3K27M DIPG. (A) Gene expression heatmap for all genes on chromosome 4q 
across three independent platforms, separated by those with 4q loss (blue) and those with 
normal copy number (grey). Agilent, left (n=67); Affymetrix, middle (n=102); RNAseq, right 
(n=82). (B) CIRCOS plots for 6 cases (5x H3.3K27M DIPG, 1x midline histone wild-type) with 
complex rearrangements leading to TOP3A amplification. In each case, plots provide DNA 
copy number changes (dark red, amplification; red, gain; dark blue, deletion; blue, loss) and 
loss of heterozygosity (yellow) on the inner rings, and intra- (orange) and inter- (blue) 
chromosomal translocations inside the circle. 
 
 
  
  
Figure S6 (related to Figure 6) – Somatic mutations in pHGG/DIPG. (A) Mutation rate boxplots 
across non-hypermutator pHGG/DIPG separated according to location (n=318), histone 
mutation(n=326), methylation subgroup (n=129), pre/post-treatment sampling (n=326) and 
age <1 year (n=326), and then compared to 11 hypermutator cases (plotted on a log10 scale). 
The thick line within the box is the median, the lower and upper limits of the boxes represent 
the first and third quartiles, and the whiskers 1.5x the interquartile range. *** adjusted 
p<0.0001, **<0.01, t-test.  (B) Mutation signatures for the 11 hypermutator cases. (Top) Simple 
stacked barplot representation of the proportion of mutation types observed in individual 
hypermutator cases and the remaining accumulated dataset. Base changes given in the key. 
(Bottom) Mutation context given for each of the 96 mutated trinucleotides, represented by 
heatmap. The base located 5′ to each mutated base is shown on the vertical axis, and the 3′ 
base is on the horizontal axis. (C) Oncoprint representation of an integrated annotation of 
somatic mutations and DNA copy number changes in IDH1 mutant cases (n=14). 
Clinicopathological and molecular annotations are provided as bars according to the included 
key. (D) Mutual exclusivity analysis. Pairwise Fishers exact tests are calculated for each of 
the 30 most commonly altered genes in pHGG/DIPG. Log2-transformed odds ratios are plotted 
in a purple (negative correlation) to cyan (positive correlation) color scheme. White boxes 
represent no co-occuring events. *** adjusted p<0.001, ** adjusted p<0.01, *adjusted p<0.05. 
(E) Coverage and variant allele frequency (VAF) statistics for rare variants. (a) Coverage and 
(b) VAF are provided as a density plot for those variants detected in 1-3 cases (blue lines) 
overlaid with the remaining variants (shaded grey). (c) Co-plot of VAF (blue points) and 
coverage (grey bars) for variants detected in a single case, ordered by VAF. 
 
 
  
  
  
  
  
  
  
  
  
  
Figure S7 (related to Figure 7) – Integrated pathway analysis of pHGG/DIPG. (A) TP53 / DNA 
repair pathway, (B) chromatin readers, writers, remodellers, (C) cell cycle pathway, (D) 
receptor tyrosine kinases, (E) PI3K/mTOR pathway, (F) MAPK pathway, (G) BMP pathway, 
(H) WNT pathway and (I) maintenance of genome integrity. (a) Oncoprint representation of an 
integrated annotation of somatic mutations and DNA copy number changes in cases targeting 
one or more members of a specific pathway. Clinicopathological and molecular annotations 
are provided as bars according to the included key. (b) Anatomical location of pathway-
targeted cases. Radius of circle is proportional to the number of cases. Left – sagittal section 
showing internal structures; right – external view highlighting cerebral lobes. Black = given 
pathway alteration. Lighter shaded circles represent a non-specific designation of 
hemispheric, midline or brainstem. (c) Boxplot showing age at diagnosis of included cases, 
separated by pathway-targeted cases. The thick line within the box is the median, the lower 
and upper limits of the boxes represent the first and third quartiles, and the whiskers 1.5x the 
interquartile range. (d) Kaplan-Meier plot of overall survival of cases separated by pathway-
targeted cases, p value calculated by the log-rank test. (e) Barplots showing distribution of 
pathway-targeted cases by anatomical location, histone subgroup, methylation subgroup and 
age. *** p<0.001, ** p<0.01, *p<0.05, n.s., not significant, t-test. 
 
 
  
  
Figure S8 (related to Figure 8) – Integrated analysis of H3/IDH1 wild-type pHGG/DIPG. (A-C) 
Unsupervised hierarchical clustering of the most variable genes in samples profiled by (A) 
Agilent arrays (n=67), (B) Affymetrix arrays (n=102) and/or (C) RNA sequencing (n=82). (D) 
A combined dataset across all platforms (n=220) is subjected to differential expression 
analysis for H3.3G34R/V, H3.3K27M and H3.1K27M mutations, with significant genes plotted 
in the heatmap. (E) Gene set enrichment analysis for selected significant gene sets for each 
comparison. (F) Combined dataset for H3/IDH1 wild-type clusters WT-A, WT-B and WT-C 
(n=21), with significantly differentially expressed genes plotted in the heatmap. (G) Gene set 
enrichment analysis for selected significant gene sets for each comparison. 
Clinicopathological and molecular annotations are provided as bars according to the included 
key. 
	
